Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KCNMA1 antisense RNA 3 (KCNMA1-AS3) is a non-coding RNA gene classified as a long non-coding RNA (lncRNA)[1]. There is very limited functional or mechanistic data available about KCNMA1-AS3 in the biomedical literature, and no established role as a therapeutic target, receptor, enzyme, or transporter has been described. The only reported disease association is with hypophosphatasia[1]. There are no known common aliases beyond those already listed, and there is no information on drugs, mechanisms, biomarker roles, or safety concerns. **Caution:** The literature and resources instead discuss KCNMA1-AS1 (KCNMA1 antisense RNA 1), a lncRNA implicated in bone formation and SMAD9 signaling[2][5]. There is no evidence that KCNMA1-AS3 is a recognized or therapeutically actionable target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on KCNMA1 antisense RNA 3 (KCNMA1-AS3).